Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic ...

We recently compiled a list of the 10 Hot Penny Stocks to Buy Now. In this article, we are going to take a look at where ...

Investment analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the specialty ...

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

State of New Jersey Common Pension Fund D raised its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – ...

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of ...